WEKO3
アイテム
新薬候補化合物の開発段階で見られた反応性代謝物による異常な薬物動態特性についての検証
https://doi.org/10.15020/00001387
https://doi.org/10.15020/0000138705667749-6c64-4495-b5ff-4f8561dc949d
| 名前 / ファイル | ライセンス | アクション |
|---|---|---|
AN10052143-20160715-124.pdf (1.0 MB)
|
|
| Item type | 紀要論文 / Departmental Bulletin Paper(1) | |||||
|---|---|---|---|---|---|---|
| 公開日 | 2016-07-15 | |||||
| タイトル | ||||||
| タイトル | 新薬候補化合物の開発段階で見られた反応性代謝物による異常な薬物動態特性についての検証 | |||||
| 言語 | ||||||
| 言語 | jpn | |||||
| 資源タイプ | ||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
| 資源タイプ | departmental bulletin paper | |||||
| ID登録 | ||||||
| ID登録 | 10.15020/00001387 | |||||
| ID登録タイプ | JaLC | |||||
| 別タイトル | ||||||
| その他のタイトル | Retrospective analysis of reactive metabolite-induced unusual pharmacokinetics of new chemical entities observed in clinical development stages | |||||
| 著者 |
伊賀, 勝美
× 伊賀, 勝美× IGA, Katsumi |
|||||
| 著者 所属 | ||||||
| 値 | 同志社女子大学薬学部医療薬学科特別任用教授 | |||||
| 著者所属(翻訳) | ||||||
| 値 | Doshisha Women's College of Liberal Arts, Faculty of Pharmaceutical Sciences, Department of Clinical Pharmacy | |||||
| 著者 外部リンク | ||||||
| 表示名 | 同志社女子大学研究者データベース - 伊賀勝美 | |||||
| URL | http://research-db.dwc.doshisha.ac.jp/rd/html/japanese/researchersHtml/2691/2691_Researcher.html | |||||
| 抄録 | ||||||
| 内容記述タイプ | Abstract | |||||
| 内容記述 | I encountered several drugs terminated at the clinical development stage because of their unusual reactive-metabolite-involved pharmacokinetic (PK) behaviors when I worked for Takeda Chemical Ind. as a general research manager of their PK study of new chemical entities from 2000 to 2005. In this paper, in order to clarify the true causes of theirtermination, I chose three typical compounds (Compounds A, B, and C) and analyzed their preclinical and clinical PK data in the light of current scientific findings on reactive-metaboliteinduced unusual PK, retrospectively. Additionally, I analyzed the data on pioglitazone and alogliptin, drugs currently used for the treatment of type-II diabetes worldwide, from the same view as above. As a result, I found that the three compounds would never have been selected as candidates for clinical development, but would have been screened out at earlier optimization stages, in the light of the guidance published by Food and Drug Administration (FDA) in 2009 regarding Metabolite in Safety Testing (MIST). As for pioglitazone and alogliptin, I found a lack of sufficient data to show their safety for long-term usage. I also identify the following factors as key to success in drug development: (i) Chemical design as a function of medical dose and treatment period (ii) Clarification of risk and benefit of newly developed medical treatment (iii) Differentiation of drug efficacy and PK of reactive metabolites (iv) Optimization of new chemical entities after entering the clinical stages (feedback from clinical development to research) (v) Specification of places (organs or tissues) where unusual tissue damages occur due to a reactive metabolite (vi) Reactivity of a reactive metabolite over metabolic de-toxicity, particularly in the disease states (vii) Carcinogenicity of a reactive metabolite (viii) Additional clinical safety study (even after marketed), as required by the FDA |
|||||
| 内容記述 | ||||||
| 内容記述タイプ | Other | |||||
| 内容記述 | 論文 | |||||
| 書誌情報 |
総合文化研究所紀要 en : Bulletin of Institute for Interdisciplinary Studies of Culture Doshisha Women’s College of Liberal Arts 巻 33, p. 124-141, 発行日 2016-07-15 |
|||||
| 出版地 | ||||||
| 出版者 | 京都 | |||||
| 出版者 | ||||||
| 出版者 | 同志社女子大学総合文化研究所 (学術研究支援課) | |||||
| ISSN | ||||||
| 収録物識別子タイプ | ISSN | |||||
| 収録物識別子 | 09100105 | |||||
| 書誌レコードID | ||||||
| 収録物識別子タイプ | NCID | |||||
| 収録物識別子 | AN10052143 | |||||
| 資源タイプ | ||||||
| 内容記述タイプ | Other | |||||
| 内容記述 | application/pdf | |||||
| ID | ||||||
| 内容記述タイプ | Other | |||||
| 内容記述 | AN10052143-20160715-124 | |||||
